StockData
MoonLake Immunotherapeutics logo

MoonLake Immunotherapeutics (MLTX) stock

MLTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 1/30
$11.03+0.24 (+2.22%)

Close on Nov 19, 2026Market cap $938.73MP/E –Yield –

MoonLake Immunotherapeutics gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

No gross profit figures for MoonLake Immunotherapeutics

MoonLake Immunotherapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More MoonLake Immunotherapeutics figures

See a number that looks wrong?